BioPharma Credit Plc (BPCP) ORD USD0.01(GBP)
Sell:67.40p
Buy:71.20p
0
Change:
0.1p
(0.14%)
0.1p
(0.14%)
Market closed |
Prices as at close on 10 December 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
- Add to watchlist
- Create an alert
- This stock can be held in a
Sell:67.40p
Buy:71.20p
Change:
0.1p
(0.14%)
0.1p
(0.14%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Market closed |
Prices as at close on 10 December 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Sell:67.40p
Buy:71.20p
Change:
0.1p
(0.14%)
0.1p
(0.14%)
Market closed |
Prices as at close on 10 December 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Open:
69.40p
69.40p
Trade high:
68.31p
68.31p
Year high:
76.00p
76.00p
Estimated NAV:
98.78
98.78
Previous close:
69.40p
69.40p
Trade low:
68.27p
68.27p
Year low:
65.20p
65.20p
Premium/Discount:
-11.92%
-11.92%
Previous:
0.40p (0.57%) Previous:
0.40p
0.40p (0.57%) Previous:
0.40p
Volume:
10,001
10,001
Dividend yield:
8.05%
8.05%
Currency:
GBX
GBX
Data delayed by at least 15 minutes.
Price
-
Net Asset Value (NAV)
Performance
Not available for this stock.
Trust Basics
| Benchmark: | No benchmark |
|---|---|
| Annual management charge: | 1% of Net Assets |
| Performance fee: | Yes |
| Ongoing charge: | 1.14% |
| Dividend yield: | 8.05% |
| Dividend frequency: | Quarterly |
| Total assets: | £1,175m |
| Gross gearing: | 0% |
| Market capitalisation:Market cap.: | £1,035m |
| Shares in issue: | 1.19 bn |
| Legal structure | Closed Ended Investment Company |
| Domicile: | United Kingdom |
| ISIN | GB00BDGKMY29 |
Dividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
Objective
To generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company will seek to achieve its investment objective predominantly through direct or indirect exposure to Debt Assets, which include Royalty Investments, Senior Secured Debt, Unsecured Debt and Credit Linked Notes.
NET ASSET VALUE (NAV)
| Estimated NAV: | 98.78p |
|---|---|
| Latest actual NAV: | 76.72p |
| Latest actual NAV date: | 31 October 2024 |
| Premium/Discount: | -11.92% |
| 12m average Premium/Discount: | -11.04% |
| NAV frequency: | Monthly |
| Security | Weight |
|---|---|
| Collegium | 18.98% |
| Lumira Dx | 11.34% |
| Insmed Inc | 11.00% |
| Coherus | 9.41% |
| BioCryst Pharmaceuticals Inc | 9.15% |
| Bms | 6.75% |
| OptiNose Inc | 5.38% |
| Evolus | 3.77% |
| Urogen | 3.77% |
| Immunogen Inc | 2.82% |
Top 10 sectors currently unavailable.
| Country | Weight |
|---|---|
| United States | 28.36% |
Key Dates
| Launch date: | 22 March 2017 |
|---|---|
| Financial year end: | December |
| Next AGM: | May 2025 |
Data policy -
All information should be used for indicative purposes only. You should independently
check data before making any investment decision. HL cannot guarantee that the data is
accurate or complete, and accepts no responsibility for how it may be used.
Prices provided by NBTrader. Charts provided by Factset.
Dividend data provided by Digital Look. Recent trade data provided by MoneyAM. Trust basics,
holding data, key dates, objective and NAV provided by Morningstar.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.